Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune,...
Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% o...
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(3.32) per share which missed the analyst consensus estimate of $(3.11...
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end– ...
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulce...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programsPatent includes broad claims for "Gut...
